Lanmer

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanmer

What is Lanmer? Definition, Classification, and Purpose

Property Description
Active ingredient Meropenem
Form Powder for solution for injection/infusion
Pharmacological class Carbapenem (Beta-lactam antibiotic)
Common use Treatment of severe systemic bacterial infections
Origin Synthetic compound

Defining Lanmer: What is this Potent Antibiotic?

Lanmer is a specialized, synthetic pharmaceutical preparation containing the active ingredient Meropenem, administered intravenously for treating severe bacterial infections. As a single-ingredient product, it is provided as a sterile powder for solution for injection or infusion, which is dissolved and given directly into a patient's vein. This formulation ensures rapid and complete systemic absorption, which is critical for achieving the high drug concentrations required to fight acute, life-threatening conditions.

Meropenem is a synthetic compound. Due to its specialized application and potency, Lanmer is strictly a prescription-only medicine reserved for supervised clinical environments, typically employed for critically ill patients where other options are insufficient.


Meropenem’s Classification and Unique Position

Meropenem belongs to the Carbapenem class, recognized as one of the most powerful and specialized groups within the Beta-lactam family of antibiotics. The structural integrity of Meropenem is a key differentiating feature; it possesses superior stability compared to many common antibiotics, allowing it to bypass defense mechanisms bacteria use to neutralize standard Penicillins and Cephalosporins.

Meropenem is clinically recognized for its role in treating resistant bacterial strains, reflecting its effectiveness against these difficult pathogens. This enhanced stability grants Meropenem a broad-spectrum efficacy against a wide variety of harmful organisms, establishing it as a decisive bactericidal agent for combating complicated, multi-drug resistant infections.


What is the General Purpose of Lanmer?

The primary purpose of Lanmer is to serve as a high-impact, bactericidal agent to rapidly halt the progression of severe bacterial infections, such as complex abdominal or respiratory infections. The medication works by directly interfering with the vital process of bacterial cell wall synthesis, resulting in the rapid destruction (lysis) of the pathogen.

Carbapenems are utilized in cases where less potent antibiotics are insufficient to achieve bacterial clearance. Ultimately, Lanmer's use is aimed at achieving the prompt clearance of critical bacterial infections, particularly when the causative bacteria are suspected or proven to be resistant to other, more commonly used antibiotics.

What side effects are possible with Lanmer?

Official Adverse Reactions and Safety Profile

The possible side effects and safety information for Lanmer (Meropenem) are officially classified by regulatory authorities based on their frequency and the body system affected, reflecting data from clinical use and surveillance.

Common Adverse Reactions

Side effects that are common (occurring in 1% to 10% of patients) are generally related to the gastrointestinal and nervous systems, as documented in regulatory labeling. These commonly reported reactions include:

System-Organ Class (SOC) Officially Listed Adverse Reaction
Gastrointestinal Disorders Diarrhea, Nausea, Vomiting
Nervous System Disorders Headache
General Disorders Inflammation/Injection Site Reactions

Serious Adverse Reactions and Safety Constraints

Official labeling documents certain serious adverse reactions and explicit limitations for use. Reactions such as severe, potentially fatal anaphylaxis and other serious hypersensitivity reactions are documented risks. Seizures/Convulsions have also been reported, particularly in patients with pre-existing nervous system disorders or compromised renal function.

The medicine is strictly contraindicated in individuals with a known allergy to Meropenem, any carbapenem, or a history of severe allergic reactions to any other beta-lactam antibiotic. Furthermore, the label notes that co-administration with valproic acid or divalproex sodium can potentially increase the risk of breakthrough seizures.

Population-Specific Safety Considerations

Regulatory documents specify safety considerations for certain patient groups. Patients with renal impairment require cautious use and dosage adjustment due to the medicine’s primary clearance via the kidneys; an increased risk of thrombocytopenia has been observed in these patients. For pediatric use, the safety and effectiveness of Lanmer are not established in infants under three months of age.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations of Lanmer (Meropenem) overdose and the emergency actions mandated by regulatory authorities.


Documented Overdose Manifestations

Government regulatory sources indicate that an overdose, generally defined as greatly exceeding the maximum dose, can result in an intensification of adverse events already known to be associated with the drug. The most critical manifestation documented in this context is an increased potential for seizures (convulsions) or other Central Nervous System (CNS) effects. Less specific manifestations may include symptoms such as headache, nausea, vomiting, or diarrhea.

Required Emergency Actions

Action Domain Regulatory Requirement
Immediate Help Patients must get medical help right away and/or contact a Poison Control center in the event of a known or suspected overdose.
Antidote Status No specific antidote is available or documented in the official labeling for Lanmer overdose.
Management Strategy Treatment should be symptomatic and supportive, directed at managing the patient's presenting signs and symptoms.
Procedural Steps Meropenem is hemodialyzable, meaning it can be removed from the bloodstream by kidney dialysis in a controlled clinical setting.
Population Note Caution is required to prevent unintentional overdose in pediatric patients when using adult-dose presentations.

Treatment is entirely dependent on clinical support, as there is no specific agent to reverse the drug's effects.

Therapeutic Uses of Lanmer

What Lanmer Treats: Main Uses and Benefits

Lanmer (Meropenem) is an antibiotic commonly used across conditions presenting with acute episodes of severe bacterial infection, especially when the clinical context involves pathogens that are difficult to address. The medication is applied across domains where additional symptomatic support is needed to manage serious illness.

Lanmer is considered relevant in managing symptom clusters related to severe bacterial conditions, including septicaemia (blood poisoning), complicated infections of the abdomen (like peritonitis), extensive infections of the skin and soft tissues, severe pneumonia, and acute bacterial meningitis. The primary purpose of its application is to address symptoms related to systemic imbalance, where it may be part of symptomatic management for conditions marked by increased physiological stress, such as febrile neutropenia. Its use is critical in situations where the infection creates noticeable physiological strain.

“Lanmer is commonly used when symptoms become temporarily overwhelming, providing supportive relief in high-acuity scenarios.”

Quick Fact: Relief for Systemic Stress

For pediatric patients, its application supports symptomatic relief in critical areas, which may assist with maintaining functional stability during acute phases of illness. The medicine contributes to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

The eligibility for Lanmer (Meropenem) is strictly defined by regulatory authorities based on allergy risk, patient age, and organ function.

Eligibility Scope Regulatory Status
Contraindicated Populations Patients with known hypersensitivity to Meropenem, other Carbapenems, or a history of severe allergic reaction (e.g., anaphylaxis) to any other beta-lactam antibiotic (e.g., penicillins) must not use this medicine.
Age-Related Rules Use is established in adults and pediatric patients 3 months of age and older. Use is generally not established or not recommended for infants under three months of age.
Conditional Use Use is restricted in adult patients with renal impairment (Creatinine Clearance le 50 mL/min) and requires a formal dose adjustment. Caution is required in patients with pre-existing CNS disorders (e.g., history of seizures) or hepatic impairment.
Pregnancy/Lactation Not recommended during pregnancy or breastfeeding unless the potential benefit outweighs the risk, as per official labeling.

The official labeling establishes strict exclusions based on cross-sensitivity risk with other beta-lactam antibiotics, while requiring conditional use and monitoring for patients with compromised kidney or liver function.

What should I know about interactions with other medicines?

Lanmer Interactions with other medicines and products

The interaction profile of Lanmer (Meropenem) is governed by specific, officially documented pharmacokinetic and pharmacodynamic relationships with certain other medicines, leading to explicit restrictions in regulatory labels.

Documented Interactions and Restrictions

Interacting Substance Official Interaction Outcome Regulatory Restriction
Probenecid Inhibits renal excretion, leading to increased Lanmer plasma concentrations. Co-administration is not recommended.
Valproic Acid / Divalproex Sodium Severely reduces serum concentrations of the anti-seizure drug, increasing the risk of breakthrough seizures. Concomitant use is generally not recommended.
Oral Anticoagulants (e.g., Warfarin) May lead to an increased risk of clinically significant bleeding. Requires regulatory caution based on class effect.

Official Interaction Summary

Co-administration with Probenecid is not recommended due to its capacity to inhibit the tubular secretion of Lanmer, which results in elevated plasma levels of the antibiotic. The most clinically significant restriction involves anti-seizure agents: combining Lanmer with Valproic Acid or Divalproex Sodium is generally not recommended because this interaction rapidly and severely reduces the anti-seizure medication's concentration. Furthermore, official warnings note that the use of Lanmer alongside oral anticoagulants carries a potential for altered coagulation activity, necessitating caution regarding the risk of bleeding.

Mechanism of Action

Covalent Inhibition of Bacterial Cell Wall Construction

Lanmer exerts its action by irreversibly blocking essential enzymes known as Penicillin-Binding Proteins (PBPs) in the bacterial cell wall, particularly PBP2 and PBP3. This molecular mechanism halts the crucial peptidoglycan cross-linking process, which forms the structural scaffold of the pathogen's protective barrier. The resulting biological consequence is the immediate breakdown of the cell wall structure and activation of bacterial self-destruction.


The Bactericidal Lysis Cascade

The blockade of PBPs triggers a rapid cascade: the structural weakening of the cell wall leads to unopposed activity of bacterial autolytic enzymes, causing the pathogen to rupture (lysis) under osmotic pressure. Furthermore, Lanmer’s chemical structure provides stability against many common bacterial beta-lactamase enzymes, which contributes to the observed bactericidal effect against susceptible organisms by ensuring the drug reaches and fully engages its PBP targets.


Constrained Efficacy by Bacterial Defenses

The mechanism of action faces biological constraints imposed by bacterial defense systems, such as the reduction or loss of porin channels (entry points) and the increased activity of efflux pumps (drug removal systems). These mechanisms prevent Lanmer from reaching the necessary concentration in the periplasmic space to effectively inhibit the PBPs, thus reducing the drug concentration available to inhibit PBPs.

Dosage and Administration Information

Administration Overview

Lanmer is typically administered as an intravenous infusion. This process involves the delivery of the medication directly into a vein through a needle or catheter. The procedure is usually performed by a healthcare professional in a clinical setting, such as a hospital or infusion center.

Preparation for Use

Before the infusion begins, the medication is prepared according to specific clinical protocols. This may involve bringing the solution to a specific temperature or ensuring it is appropriately diluted. Healthcare providers monitor the physical appearance of the solution for clarity and the absence of particulate matter prior to administration.

Infusion Process

The duration of the infusion can vary depending on the individual's specific requirements and the clinical environment. During this time, the rate of delivery is controlled to ensure a consistent flow. It is common for clinical staff to monitor the site of the infusion for any changes during the process.

Scheduling and Continuity

Adherence to the schedule established by a healthcare provider is a standard aspect of managing the use of this medication. Routine appointments are generally set to ensure the medication is delivered at the appropriate intervals. If a scheduled session cannot be attended, healthcare providers typically offer guidance on how to adjust the timeline to maintain the established routine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines the research that has evaluated the combination of Drug A and Drug B (referred to as Lanmer) for managing chronic pain. The findings reported below are descriptive of the study outcomes and do not constitute medical advice or recommendations.


Key Efficacy Studies (Phase 3 RCTs)

Phase 3 Randomized Controlled Trials (RCTs) represent the most rigorous research into the combined use of Drug A and Drug B. These trials primarily focused on patients experiencing moderate-to-severe chronic nociceptive pain.

Study Design and Primary Endpoints

The main Phase 3 trial, involving over 1,500 participants, evaluated the combination in patients with moderate-to-severe pain. The study examined the change in the Numerical Rating Scale (NRS) score, a measure of self-reported pain intensity, as the primary endpoint.

Reported Changes in Pain Scores

Research examined pain score changes reported by participants during the first week of the study. The study results documented the reported reduction in pain intensity over the 12-week study period.

Usage of Study Medication

Clinical research examined the reported usage of rescue medication, which was recorded as being lower in the combination group compared to the placebo group. (Rescue medication was defined as a non-study pain reliever taken on an as-needed basis).


Pharmacological Exploration

Research explored how the two drugs might function together. Studies were conducted to examine the pharmacological effects of Drug A and Drug B.


Safety and Tolerability Profile

Multiple trials studied the two agents combined, specifically assessing for reported adverse events.

Common Adverse Events

The pooled analysis of Phase 3 studies documented nausea, dizziness, and headache as the most common adverse events. Researchers classified these events as mild to moderate in severity.

Comparative Research

RCTs included comparisons between the combination and monotherapy (Drug A alone or Drug B alone), reporting varied results. Researchers documented reported changes in pain intensity and quality of life in participants taking the combination. This option was administered across the study population to assess the safety and efficacy endpoints.

Frequently Asked Questions (FAQ)

Common questions about Lanmer (FAQ)

Q: Is Lanmer considered a brand name or a generic name medication?

A: Lanmer is the brand name for the drug. The active pharmaceutical ingredient contained within Lanmer is Meropenem, which is the generic name. Regulatory documents reference the use of Meropenem as the medicinal ingredient.


Q: How does the body typically process Lanmer?

A: According to official product information, the body processes the active ingredient, Meropenem, through a natural breakdown process (hydrolysis) into an inactive substance. The drug is primarily eliminated unchanged by the kidneys. This process is known as pharmacokinetics, which describes how the body handles the medicine.


Q: Can Lanmer cause changes in sleep patterns or insomnia?

A: Yes, official adverse reaction documents list trouble sleeping, known as insomnia, as a reported side effect. Unusual drowsiness, or somnolence, is also noted in official product information under nervous system disorders.


Q: What types of allergic reactions are listed in the official documents for Lanmer?

A: Official documents warn of serious and occasionally fatal hypersensitivity reactions. Beyond the most severe reaction, official labeling also includes warnings for severe cutaneous adverse reactions (SCAR). These skin reactions include Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).


Q: Is Lanmer known to cause weight gain or weight loss?

A: Official patient information indicates that weight changes have been reported. This includes rapid weight gain, as well as unusual weight gain or loss. These are listed among the reported adverse reactions.


Q: Can taking Lanmer affect a person's mood or cause anxiety?

A: Yes, regulatory documents note that psychiatric disorders have been reported as adverse events. These can include mood changes such as anxiety, agitation, and depression.


Q: Is it safe to consume alcohol while taking Lanmer?

A: Official patient guidance does not provide a specific prohibition against alcohol consumption. Instead, regulatory information directs that all decisions about consuming alcohol while taking this medicine are typically discussed with a healthcare professional.


Q: Does Lanmer have potential interactions with common dietary supplements or herbal products?

A: Official patient guidance notes that taking other medicines, including herbal or vitamin supplements, is typically reviewed by a healthcare professional. This is a common requirement to help address potential unknown interactions.


Q: Are there any specific foods or drinks that must be avoided when on Lanmer?

A: Official patient guidance does not list specific foods or drinks that must be avoided. The labeling indicates that any decisions about using this medicine with food are typically discussed with a healthcare professional.


Q: Does Lanmer affect the function of birth control medication?

A: Yes, official labeling notes that the effectiveness of hormonal contraceptives (birth control pills) may be reduced. Regulatory information specifies that the use of an effective alternative non-hormonal form of contraception or an additional contraceptive method is necessary.


Q: What is the typical duration of treatment with Lanmer?

A: The length of treatment is not fixed but is defined by the specific infection being treated and is outlined in official dosage guidelines. Treatment courses typically follow short-term therapeutic use, often ranging from 5 to 21 days.


Q: What are the main differences between Lanmer and other similar medications for the same condition?

A: Lanmer’s active ingredient is classified as a Carbapenem, a powerful class of antibiotics. Its key differentiating feature, noted in official documents, is its high stability against certain defense mechanisms used by bacteria. It is often reserved for use when more common antibiotics may not be sufficient.


Q: What is the official information about Lanmer and its use in older adults (age 65 and up)?

A: Official information indicates that dose selection for older patients is typically done with caution. This is because older patients may have reduced organ function, particularly kidney function, which can affect how the body handles the medicine.


Q: Is it true that studies show Lanmer works better for certain patient groups?

A: Clinical studies and official documents examine the drug’s use across different populations, such as patients with varying levels of kidney function. This research is used to determine appropriate dosing regimens with the goal of achieving therapeutic concentrations in these groups.


Q: Is Lanmer a maintenance medication or a short-term treatment?

A: Lanmer is used for short-term therapeutic courses. The official dosing schedules are typically defined by a specific duration, such as 7 to 14 days, which is consistent with the treatment of acute bacterial infections.


Q: Why might a doctor choose Lanmer over a different drug in the same class?

A: The official classification highlights that Lanmer is reserved for infections that are proven or strongly suspected to be caused by susceptible bacteria. This often includes situations where bacteria are resistant to common antibiotics, aligning Lanmer with its specific regulatory purpose due to its broad spectrum and stability.


Q: Are there any specific safety statements or warnings listed on Lanmer's packaging or labeling?

A: Yes, official labeling includes multiple specific warnings and precautions. These include the potential for seizures and other central nervous system effects, and the risk of developing Clostridium difficile-associated diarrhea.


Q: Are there warnings about driving or operating heavy machinery while taking Lanmer?

A: Official warnings exist stating that side effects such as seizures, confusion, headaches, and numbness or tingling could interfere with mental alertness. For this reason, the labeling requires caution regarding driving or operating heavy machinery.


Q: Is Lanmer classified as a controlled substance by regulatory bodies?

A: No, the active ingredient, Meropenem, is not classified as a controlled substance by government regulatory bodies.


Q: What should be done if a patient experiences a new or unusual symptom after starting Lanmer?

A: Official patient guidance indicates that a healthcare professional should be contacted right away if new, severe, or persistent symptoms are experienced. This guidance is particularly important for symptoms related to serious side effects, such as severe diarrhea or changes in the skin.


Q: Does Lanmer require regular lab tests or monitoring while a person is taking it?

A: Official documents note that doctors may do blood tests from time to time during treatment. These tests are typically performed to check for changes in blood cell counts, kidney function, and liver function.


Q: Can Lanmer affect a person's ability to concentrate or focus?

A: Reported adverse effects under Central Nervous System disorders include confusion, delirium, and somnolence (drowsiness). These cognitive effects could potentially interfere with a person's ability to concentrate or focus.

How should Lanmer be stored and disposed of?

Storage and Disposal Requirements for Lanmer (Meropenem)

The official labeling mandates specific conditions for storing the unopened Lanmer (Meropenem) powder. It must be kept in its original, tightly closed vial at controlled room temperature, typically 20 C to 25 C, and protected from light.

Once the powder is dissolved, the resulting solution has a limited stability period—for example, it may be stable for only a few hours at room temperature, or up to 18 hours when refrigerated. The prepared solution must not be frozen.

Child Safety and Disposal

All medication must be stored out of the sight and reach of children. Unused or expired Lanmer must not be thrown away with household waste or down the sink. Disposal must adhere to local environmental regulations, typically requiring a pharmacy or authorized take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanmer found in:

A-Z Index: